Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine

Robert Zivadinov, Dejan Jakimovski, Sirin Gandhi, Rahil Ahmed, Michael G. Dwyer, Dana Horakova, Bianca Weinstock-Guttman, Ralph R H Benedict, Manuela Vaneckova, Michael Barnett, Niels Bergsland

Research output: Contribution to journalReview article

Abstract

Introduction: Brain atrophy measurement in multiple sclerosis (MS) has become an important outcome for determining patients at risk for developing physical and cognitive disability. Areas covered: In this article, we discuss the methodological issues related to using this MRI metric routinely, in a clinical setting. Understanding trajectories of annualized whole brain, gray and white matter, thalamic volume loss, and enlargement of ventricular space in specific MS phenotypes is becoming increasingly important. Evidence is mounting that disease-modifying treatments exert a positive effect on slowing brain atrophy progression in MS. Expert Commentary: While there is a need to translate measurement of brain atrophy to clinical routine at the individual patient level, there are still a number of challenges to be met before this can actually happen, including how to account for biological confounding factors and pseudoatrophy, standardize acquisition and analyses parameters, which can influence the accuracy of the assessments.

Original languageEnglish
Pages (from-to)777-793
Number of pages17
JournalExpert Review of Neurotherapeutics
Volume16
Issue number7
DOIs
Publication statusPublished - Jul 2 2016

Keywords

  • biological confounding factors
  • brain atrophy
  • clinical routine
  • cognition
  • disability
  • disease-modifying treatment
  • gray matter
  • measurement
  • Multiple sclerosis
  • pseudoatrophy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine'. Together they form a unique fingerprint.

  • Cite this

    Zivadinov, R., Jakimovski, D., Gandhi, S., Ahmed, R., Dwyer, M. G., Horakova, D., Weinstock-Guttman, B., Benedict, R. R. H., Vaneckova, M., Barnett, M., & Bergsland, N. (2016). Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Review of Neurotherapeutics, 16(7), 777-793. https://doi.org/10.1080/14737175.2016.1181543